multiple sclerosis drugs such as glatiramer acetate can now be used to fight against some multi resistant bacteria , which pose a huge problem in variety of treatments in hospitals

- Glatiramer acetate, which is normally used for treating multiple sclerosis can now be used to fight against multiresistant bacteria
- The drug has shown to kill half of Pseudomonas bacteria found in cystic fibrosis patient's lungs
- The drug is relatively old and safe and less time consuming, when compared to the new drugs which are being developed
Laboratory experiments have shown that the drug kills half of the Pseudomonas bacteria in specimens from patients with cystic fibrosis who are often exposed to the bacteria in the lungs.
The discovery is good news at a time where multi-resistant bacteria are a growing problem.
"We see great perspectives in the discovery because our data shows that the drug is effective against infections that occur because of what are known as Gram-negative bacteria. These bacteria form the basis of diseases such as pneumonia, cystitis and septic shock. Due to growing resistance, we are experiencing a decline in the number of effective treatments against them, and some of the medicaments which we otherwise know to be effective must be given in such high doses to be effective that they become toxic for the patients," explains Professor with special responsibilities (MSO) Thomas Vorup-Jensen from the Department of Biomedicine at Aarhus University.
According to a British survey commissioned by the British government, in 2050 resistant bacteria will all-in-all kill more people around the world than cancer.
Neither the pharmaceutical industry or researchers have so far succeeded in developing new types of antibiotics that can beat the bacteria following classic strategies for the development of new medicines.
This is where researchers and companies test already approved medicines or substances on other diseases or functions of human biology than those they were originally developed for.
"The results give us greater knowledge about how the drug works on sclerosis patients and indicates at the same time that bacteria might be part of the problem with the disease. This is also indicated by some studies," says Thomas Vorup-Jensen.
Aarhus University is collaborating with Aarhus University Hospital, Imperial College London, UK, Harvard Medical School, Boston, USA and the British pharmaceutical company Cycle Pharmaceuticals, who specialise in the recycling of medicine.
Reference
- Stig Hill Christiansen, Ronan A. Murphy, Kristian Juul-Madsen, Marlene Fredborg, Michael Lykke Hvam, Esben Axelgaard, Sandra M. Skovdal et.al. The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria, Scientific Reports (2017).doi:10.1038/s41598-017-15969-3
Source-Eurekalert